PRESS & NEWS
CurePSP Ask the Doctor: January 25, 2021
The coronavirus COVID-19 vaccine and progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) will be the topic during a webinar on Monday, January 25, 2021. Dr. Lawrence I. Golbe, Director of Clinical Affairs for CurePSP, will be the presenter at this 30-minute webinar that begins at 2:00 p.m. Eastern Standard Time…
The coronavirus COVID-19 vaccine and progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) will be the topic during a webinar on Monday, January 25, 2021. Dr. Lawrence I. Golbe, Director of Clinical Affairs for CurePSP, will be the presenter at this 30-minute webinar that begins at 2:00 p.m. Eastern Standard Time (11:00 a.m. Pacific).
Dr. Globe, who also serves as chair of CurePSP’s Medical Advisory Board, has written an advisory memo on this subject. PSP, CBD and MSA are conditions that increase the risk of death from Covid-19 and therefore should qualify as underlying conditions warranting priority for receiving a Covid vaccine.
This webinar will be moderated by Joanna Teters, CurePSP’s community outreach and resource manager. Questions can be submitted in advance at info@curepsp.org or through the registration link.
Dr. Golbe will answer questions that were submitted during registration by patients and families. He cannot give case-specific medical advice, and any medications that are mentioned during the webinar should not be tried unless under the supervision of a licensed professional.
Watch the recorded webinar below.
About Dr. Larry I. Golbe
Dr. Golbe is Emeritus Professor of Neurology at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ. He graduated from Brown University and New York University School of Medicine and did residency training at NYU/Bellevue before assuming his current position. He was Acting Chair of the department from 2000 to 2003 and Program Director of its neurology residency from 2003 to 2018.
Dr. Golbe’s research is in the clinical genetics, clinimetrics, and epidemiology of parkinsonian disorders. In 1988 he co-led the first studies of the prevalence and risk factors in PSP. He led the clinical portion of the project that in 1997 identified the first known Mendelian mutation causing Parkinson’s disease in the gene for alpha-synuclein. He devised the PSP Rating Scale, which since its publication in 2007 has become the standard clinical measure and treatment outcome marker for PSP worldwide.
He has a referral practice for patients with PSP and CBD and conducts multiple ongoing research studies. He has worked closely with CurePSP since 1992, presently as Director of Clinical Affairs, chair of its Medical Advisory Board, and a member of its Board of Directors.
About CurePSP
CurePSP is a nonprofit organization working to increase awareness, advocate for patients and families, and fund research for devastating prime of life neurodegenerative diseases, including PSP, CBD, and MSA. CurePSP provides advocacy and support for patients, families, and caregivers; education for physicians and allied healthcare professionals; and funding for research.
Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.